CytomX Therapeutics, Inc. Common Stock (CTMX) Stock
Key stats
- Market cap
- $464.35M
- Price / Earnings ratio
- -4.9x
- EPS (TTM)
- -$0.50
- Volume
- Loading
- 52-week high
- $8.21
- 52-week low
- $1.90
Source: third-party data provider, as of November 13, 2026
Compare with CTMX
Recent news

CytomX Therapeutics Q2 Earnings Call Highlights
CytomX Therapeutics Q2 Earnings Call Highlights
CTMX

CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates
CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates
CTMX

CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why
CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why
CTMX

CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue Estimates
CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue Estimates
CTMX
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 42.00
- MACD 12/26/9
- -0.15
- EMA 9 of MACD
- -0.14
- MACD histogram
- -0.00
- SMA 50
- $2.63
- Price below SMA 50
- EMA 50
- $2.56
- Price below EMA 50
- SMA 200
- $3.75
- Price below SMA 200
- EMA 200
- $3.53
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

CytomX Therapeutics Q2 Earnings Call Highlights
CytomX Therapeutics Q2 Earnings Call Highlights
CTMX

CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates
CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates
CTMX

CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why
CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why
CTMX

CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue Estimates
CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue Estimates
CTMX

CTMX Stock Garners Price Target Revisions After Colorectal Cancer Trial Data: Jefferies Sees As Much As 230% Upside
CTMX Stock Garners Price Target Revisions After Colorectal Cancer Trial Data: Jefferies Sees As Much As 230% Upside
CTMX

CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data
CTMX

CTMX Stock Pulls Back After 5-Year High: Share Sale Sparks Dilution Fears Despite Wall Street’s 150% Upside Calls
CTMX Stock Pulls Back After 5-Year High: Share Sale Sparks Dilution Fears Despite Wall Street’s 150% Upside Calls
CTMX

Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data
Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data
CTMX

CytomX Therapeutics (CTMX) Reports Q4 Loss, Misses Revenue Estimates
CytomX Therapeutics (CTMX) Reports Q4 Loss, Misses Revenue Estimates
CTMX

Why CTMX Stock Is Soaring 54% Pre-Market Today?
Why CTMX Stock Is Soaring 54% Pre-Market Today?
CTMX
News tone: automated (AI) classification of the article's content, not a price prediction.
About CytomX Therapeutics, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Sean A. McCarthy DPHIL | Chairman & CEO | 1967 |
| Mr. Christopher W. Ogden | SVP, CFO & Secretary | 1984 |
| Ms. Rachael Lester | Chief Business Officer & Senior VP | 1978 |
| Dr. Marcia P. Belvin Ph.D. | Senior VP & Chief Scientific Officer | 1967 |
| Ms. Alejandra Veronica Carvajal J.D. | Chief Legal Officer | 1974 |
| Ms. Danielle Olander-Moghadassian | Senior VP & Chief Human Resources Officer | — |
| Ms. Leslie Robbins J.D. | Senior Vice President of Intellectual Property | — |
| Dr. Yu-Waye Chu M.D. | Senior VP & Chief Medical Officer | 1968 |
| Ms. Dawn Benson | Senior Vice President of Quality & Product Manufacturing | — |
| Dr. Stephanie Robertson Ph.D. | Senior Vice President of Alliances & Program Leadership | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 42.00
- MACD 12/26/9
- -0.15
- EMA 9 of MACD
- -0.14
- MACD histogram
- -0.00
- SMA 50
- $2.63
- Price below SMA 50
- EMA 50
- $2.56
- Price below EMA 50
- SMA 200
- $3.75
- Price below SMA 200
- EMA 200
- $3.53
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $12.00
- Average
- $12.00
- High
- $12.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -9.0 | -35.4 | ||||||||||
| 2022 | +2.4 | -18.2 | -24.6 | -39.1 | -11.5 | +18.1 | -22.3 | +5.6 | -4.0 | -12.1 | +32.8 | -6.4 |
| 2023 | +67.7 | -19.8 | -30.4 | +5.8 | -0.6 | +2.4 | -2.2 | -11.2 | -14.0 | -12.0 | +28.7 | +9.9 |
| 2024 | -9.5 | +60.1 | -17.7 | -24.2 | -66.9 | -30.3 | +3.8 | -11.9 | +5.4 | -13.0 | +1.0 | -5.5 |
| 2025 | -19.8 | -19.0 | -1.5 | +27.6 | +248.7 | -9.6 | -7.2 | -13.2 | +53.4 | +6.6 | +8.9 | -0.7 |
| 2026 | +33.9 | -11.8 | -12.0 | -7.5 | -13.9 | +8.7 | -13.9 | +6.0 | -25.9 | -11.0 | -4.5 |



